islatravir/ulonivirine (MK-8591B)
/ Merck (MSD)
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
December 06, 2025
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
(clinicaltrials.gov)
- P2/3 | N=570 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC
New P2/3 trial • Human Immunodeficiency Virus • Infectious Disease
October 17, 2025
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
(clinicaltrials.gov)
- P2 | N=150 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Sep 2027 ➔ Sep 2031
Trial completion date • Human Immunodeficiency Virus • Infectious Disease
August 14, 2025
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
(clinicaltrials.gov)
- P2 | N=150 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting
Enrollment closed • Human Immunodeficiency Virus • Infectious Disease
May 08, 2025
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
(clinicaltrials.gov)
- P2 | N=150 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting
Enrollment open • Human Immunodeficiency Virus • Infectious Disease
March 24, 2025
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
(clinicaltrials.gov)
- P2 | N=150 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC
New P2 trial • Human Immunodeficiency Virus • Infectious Disease
June 22, 2021
Dose Ranging, Switch Study of Islatravir (ISL) and MK-8507 Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
(clinicaltrials.gov)
- P2b; N=140; Active, not recruiting; Sponsor: Merck Sharp & Dohme Corp.; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Human Immunodeficiency Virus • Immunology • Infectious Disease • CD4 • PCR
1 to 6
Of
6
Go to page
1